INTRODUCTION
HIV viral suppression is key to reducing the risk of HIV transmission, morbidity, and mortality, 1,2 and thus it is crucial for prevention and care efforts. Only 13% of HIV-positive young adults are estimated to be virally suppressed 3 and, even among those receiving medical care, HIV-positive young adults are less likely than older adults to take antiretroviral therapy (ART), be adherent, and be virally suppressed. [4] [5] [6] Agwu et al found evidence of increasing ART use and decreasing viremia from 2002 to 2010 among a cohort of youth living with HIV who were perinatally infected. 7 Recent developments in HIV care and treatment may have improved levels of viral suppression more broadly among young adults. Clinical guidelines now recommend the universal prescription of ART, and simpler, more tolerable ART regimens that may be more forgiving of nonadherence have been developed. [8] [9] [10] There has also been enhanced focus across medical, public health, and community groups on improving the HIV care continuum among youth. [11] [12] [13] However, the effect of these developments among HIV-positive youth nationally is unknown.
This analysis was guided by the following questions: have recent developments in HIV care and treatment been accompanied by increased ART prescription, adherence, and care utilization among young adults in care? If so, have these changes contributed to improvements in viral suppression? To answer these questions, we estimated temporal trends in these factors among HIV-positive young adults in care in the United States from 2009 to 2013.
METHODS

Medical Monitoring Project
We analyzed pooled data from the 2009-2013 cycles of the Medical Monitoring Project (MMP), an HIV surveillance system designed to produce annual nationally representative cross-sectional estimates of behavioral and clinical characteristics of HIV-infected adults receiving medical care in the United States and Puerto Rico. MMP methods, including sampling, weighting procedures, and response rates, have been described in detail elsewhere. 14 During these years, MMP used a 3-stage, probability-proportional-to-size sampling method. First, US states and 1 territory were sampled, then facilities providing outpatient HIV care in those areas, and finally, eligible HIV-infected patients. All sampled states and territories participated in every cycle. The facility response rate ranged from 76% to 85%, and the patient response rate ranged from 49% to 55%. Eligible persons were HIV infected, were aged 18 years or older, and received medical care in participating facilities between January and April in the cycle year for which they were sampled. Interview and medical record abstraction data were collected from June 2009 through May 2014. Data were weighted on the basis of known probabilities of selection at state or territory, facility, and patient levels. 15 In addition, predictors of nonresponse were determined from analysis of data from sampled facilities and patients, and data were then weighted to adjust for nonresponse, after established methods. 16, 17 Predictors of nonresponse varied by cycle year and project area, but in general, facility size, private practice, male gender, younger age, race/ethnicity, and shorter time since HIV diagnosis were associated with nonresponse and informed the weighting classes for the data.
In accordance with the federal human subject protection regulations 18 and guidelines for defining public health research, 19 MMP was determined to be a nonresearch, public health surveillance activity used for disease control program or policy purposes. Participating states or territories and facilities obtained local institutional review board approval to conduct MMP if required locally. Informed consent was obtained from all interviewed participants.
Analytic Methods
In this analysis, we included 636 young adults aged 18-24 years who were receiving HIV care in the United States. The sample sizes and proportions of the total MMP sample of all persons receiving HIV care by year were 2009, n = 107 (16%); 2010, n = 125 (21%); 2011, n = 127 (21%); 2012, n = 144 (22%); and 2013, n = 133 (21%). We estimated weighted percentages by year and used bivariate linear regression (ordinary least squares) to estimate trends from 2009 to 2013 in (1) ART prescription during the past 12 months, (2) regular care utilization (at least 1 viral load in each 6-month period during the past 12 months), (3) 100% adherence to ART doses during the past 3 days, (4) being bothered by ART side effects in the past 30 days, (5) taking a once-daily single-tablet ART regimen, (6) viral suppression (,200 copies/mL at last test), and (7) sustained viral suppression (,200 copies/mL at all tests during past 12 months). All measures were derived from medical record reviews except the adherence, side effects, and single-tablet regimen measures, which were self-reported. Beta-coefficients for year represent the average percentage point change from 1 year to the next. We considered trends to be statistically significant when P , 0.05. For the viral suppression measures that showed a significant trend, we used multivariate linear regression to assess how much change in viral suppression was mediated by change over time in covariates that also significantly increased over the period. We also estimated trends in selected sociodemographic characteristics collected by interview (black non-Hispanic race versus other racial/ethnic groups, male gender versus female or transgender, homosexual or bisexual identity versus heterosexual, less than high school education versus higher, at or below household poverty guideline versus over, uninsured or only Ryan White HIV/AIDS Program coverage versus private or public insurance, 5 or more years since HIV diagnosis versus less than 5 years) and HIV disease stage derived from medical record review (AIDS or nadir CD4 + 0-199 versus no AIDS and nadir CD4 + 200+) to evaluate their roles as potential confounders of change over time in viral suppression. All data were weighted for unequal selection probabilities and nonresponse.
RESULTS
The characteristics of HIV-positive young adults in care in the United States during 2009-2013 have been reported elsewhere, 4 but overall among the pooled data set (n = 636) 43% [95% confidence interval (CI): 37 to 50] were black men. Most had a gay or bisexual identity (62%, CI: 57 to 67) and were living in households at or below the poverty level (62%, CI: 56 to 66). Approximately 35% (CI: 28 to 41) were uninsured or only had Ryan White HIV/AIDS Program coverage. Over the 12 months before interview, 14% (CI: 10 to 18) reported being homeless and 11% (CI: 8 to 14) had been incarcerated. Most were diagnosed with HIV after the age of 10 years (88%, CI: 84 to 91), and three-quarters had been diagnosed for less than 5 years (75%, CI: 70 to 80). There were no significant changes in sociodemographic characteristics, time since HIV diagnosis, and HIV disease stage during 2009-2013 with the exception of an increasing proportion of men over the period (65% in 2009 to 74% in 2013, b TREND = 0.03 P TREND = 0.03, Table 1 ).
ART prescription among young adults significantly increased from 76% in 2009 to 87% in 2013 (b TREND = 0.04 P TREND = 0.01; Table 2 ). Among those taking ART, however, ART adherence and reported problems with side effects did not significantly change over the period. The proportion of young adults taking ART who reported taking a single-tablet regimen significantly increased from 49% in 2009 to 62% in 2013 (b TREND = 0.04 P TREND = 0.04). There was no significant change in regular care utilization over the period.
Although viral suppression at last test did not change over the period (65% in 2009 to 65% in 2013, b TREND = 0.02 P TREND = 0.22), the proportion of young adults who were sustainably virally suppressed significantly increased (29% in 2009 to 46% in 2013, b TREND = 0.05 P TREND # 0.01). Figure 1 illustrates these findings. The proportion of young adults who were virally suppressed at their last test and had sustained viral suppression increased from 2009 to 2013, but there was no concomitant increase in those who were virally suppressed only at their last test. Instead, the proportion who were only virally suppressed at their last visit decreased over 
DISCUSSION
We found significant improvements in sustained viral suppression from 2009 to 2013 among young adults in care, which were partially attributable to increases in the proportions of young adults who were prescribed ART and taking single-tablet regimens. However, we found no significant trend in viral suppression at last test. In any given year, only approximately 2/3 of young adults in HIV care were virally suppressed at last test, which is well short of the National HIV/AIDS Strategy 80% viral suppression goal for all diagnosed persons. 13 However, increasingly more young adults were able to maintain suppression, and a smaller proportion were only suppressed at their last test, which indicates that some progress has been made in improving health among this disproportionately affected population.
Our data show that between 2009 and 2013, providers were more likely to prescribe ART to young adults in later years and also more likely to prescribe single-tablet regimens, both of which were associated with increased levels of sustained viral suppression. During this period, guidelines for initiating ART steadily moved away from using CD4 count as a criterion for initiation, 8 and our data may reflect increasing provider adoption of these guidelines. Providers have often cited concerns about treatment readiness and other barriers to adherence as a reason to defer ART initiation for otherwise clinically eligible young people, 20,21 who on average report lower adherence than older persons. 4 However, providers may have grown less concerned about nonadherence as a reason to defer therapy among young adults because of the increasing evidence of the benefits of early ART and the availability of better regimen options that are more forgiving of nonadherence. 9 The development of multiple single-tablet regimens during this period, which are associated with better adherence, lower cost, and increased patient satisfaction, 10 also may have facilitated provider prescription of these regimens among young adults.
Despite improvements in sustained viral suppression, the prevalence of viral suppression at last test remained stable from 2009 to 2013. This stability may be due to the lack of improvement in adherence among young adults. Although one might expect that the increase in use of single-tablet regimens would be accompanied by increased adherence, it is important to note that our measure of adherence is self-reported and limited to the past 3 days, which may overestimate adherence and limit our ability to detect differences among persons due to ceiling effects. 22 It is also possible that the use of single-tablet regimens has a greater effect on nonpersistence (treatment discontinuation) rather than nonadherence (treatment interruption over a specified period); Sweet et al found that nonpersistence was higher among persons taking multitablet regimens compared with single-tablet regimens. 23 Despite the limitations of the adherence measure, the lack of improvements observed among young adults suggests that wider development and implementation of effective strategies to improve adherence among young persons may be warranted. A recent systematic review of adherence interventions for youth found that most interventions were small pilots that need to be replicated; their findings indicated that a phone-based counseling approach with adherence monitors and weekly individual and family counseling may be effective strategies for improving adherence in this population. 24 Our findings on the contribution of singletablet regimens to improvements in sustained viral suppression suggest that simplifying regimens might be an effective strategy to increase viral suppression among young adults. In addition, when selecting regimens providers may need to consider the relatively high prevalence of side effects reported by young adults, which did not decrease over the period. The development of injectable long-acting antitretrovirals may also prove to be a promising strategy for increasing viral suppression among this population. 25 This analysis has limitations. First, our patient response rates ranged from 49% to 55%, although our use of population-based sampling methods and weighting adjustments for nonresponse should reduce bias, 26 and the MMP population is demographically similar to all HIV-diagnosed persons in the United States. 27 Another potential limitation to the generalizability of our estimates is our selection of patients based on receipt of HIV care in the first 4 months of the calendar year. However, Sullivan et al 28 found that 88% of patients with HIV had a medical visit in the first 4 months of the year, although there were some clinical differences in this group compared with those seen later in the year. We should note, however, that our findings regarding trends should not be affected by these limitations, as they were consistent throughout the period. As noted earlier, our adherence measure is self-reported and only captures the past 3 days, which may overestimate adherence because of measurement error resulting from social desirability bias and limit our ability to assess changes in adherence because of ceiling effects. 22 In addition, we did not assess other potential explanatory factors for changes in viral suppression, such as changes in ART regimens. Finally, we cannot assess temporality between the self-reported interview measures and viral suppression.
In conclusion, we saw significant improvements in sustained viral suppression among HIV-positive young adults in care in the United States, which seem to be partially attributable to increases in ART prescription and use of single-tablet regimens. However, it is important to note that the level of viral suppression among young adults in care remains low; it falls short of the National HIV/AIDS Strategy goals and is significantly lower than that found for older age groups. 13 Nevertheless, the observed increases in ART prescription and sustained viral suppression among young adults in care are encouraging and suggest there may be a cause for optimism regarding efforts to improve outcomes for this vulnerable population.
